Since then, the phase III MARIPOSA and MARIPOSA-2 trials have studied the role of amivantamab and lazertinib, another potent, CNS-penetrant, third-generation EGFR TKI, as either the first line or subsequent line of treatment in advanced EFGR-mutant (ex19del and L858R) NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.